Clinical data | |
---|---|
Trade names | AiRuiYi |
Other names | Fluzoparib; SHR3162 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C22H16F4N6O2 |
Molar mass | 472.404 g·mol−1 |
3D model ( JSmol) | |
| |
|
Fuzuloparib (trade name AiRuiYi) is a pharmaceutical drug for the treatment of ovarian cancer. [1] It is approved for use in China. [2] It is an inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme. [3]
It is also being studied for its potential use for the treatment of pancreatic, breast, prostate, and lung cancer. [2]
Clinical data | |
---|---|
Trade names | AiRuiYi |
Other names | Fluzoparib; SHR3162 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C22H16F4N6O2 |
Molar mass | 472.404 g·mol−1 |
3D model ( JSmol) | |
| |
|
Fuzuloparib (trade name AiRuiYi) is a pharmaceutical drug for the treatment of ovarian cancer. [1] It is approved for use in China. [2] It is an inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme. [3]
It is also being studied for its potential use for the treatment of pancreatic, breast, prostate, and lung cancer. [2]